Neuroprotection is the most exciting claim anyone makes about these drugs and the least established — the Alzheimer’s trials have not reported yet. This analysis is a good example of how the gap between those two facts gets closed in writing rather than in data.
What was pooled
Nine observational cohort studies, 712,287 patients, searched to August 2025, comparing Parkinson’s disease incidence across antidiabetic drug classes in a Bayesian network that allowed indirect comparisons. [1] Results were expressed as risk ratios with 95% credible intervals, with prespecified subgroups by age, sex and cardiovascular disease.
What it found
In the authors’ own words in the results section: no antidiabetic class demonstrated a statistically significant difference in Parkinson’s risk.
What the analysis did produce was rank probabilities. SGLT2 inhibitors tended to rank lowest for Parkinson’s risk among people aged 75 and over, and GLP-1 agonists lowest among those under 75. Metformin, sulfonylureas and alpha-glucosidase inhibitors ranked consistently higher than the newer agents, and in people with cardiovascular disease metformin ranked higher than SGLT2 inhibitors.
The sentence that does not follow
The conclusion states that SGLT2 inhibitors and GLP-1 agonists were consistently associated with lower Parkinson’s risk, suggesting potential neuroprotective effects.
That is a stronger claim than the results support, and it is the sentence that will travel. Nothing was statistically significant; the word doing the work is “consistently,” which describes the rankings rather than the estimates. Reporting rank probabilities is normal practice and not the problem — converting them into an association is the step that does not follow, and it is the same move as reading a result into an estimate the comparison cannot carry.
And the design underneath
Nine observational cohorts, no randomization anywhere. People prescribed a GLP-1 or an SGLT2 inhibitor differ from people prescribed metformin or a sulfonylurea in age, wealth, insurance, comorbidity and how recently they entered care — and newer drugs reach systematically different patients.
Parkinson’s develops over decades and is often preceded by years of subtle symptoms. A drug prescribed more often to healthier, better-followed patients will look protective against a slow neurodegenerative disease whether or not it is, which is why pooling observational data raises precision without removing bias.
What to do with the neuroprotection story
Wait for trials. There are randomized trials running in neurodegenerative disease with readouts pending that will say more than any cohort ranking. Until those report, the honest summary is that nobody has shown these drugs prevent neurodegenerative disease, and this analysis is not an exception.
No seller on this roster claims a neurological benefit, and none should. The tell to watch for, if one ever does, is the shape of this paper: a results section that found nothing and a conclusion that found something — and whether anything is published at all to check it against.